|1.||Morré, D James: 16 articles (11/2012 - 03/2002)|
|2.||Morré, Dorothy M: 15 articles (09/2011 - 03/2002)|
|3.||Chueh, Pin-Ju: 4 articles (10/2007 - 03/2002)|
|4.||Kim, Chinpal: 3 articles (10/2010 - 03/2002)|
|5.||Tang, Xiaoyu: 3 articles (10/2010 - 01/2007)|
|6.||Cho, NaMi: 3 articles (04/2009 - 03/2002)|
|7.||De Luca, Thomas: 2 articles (08/2010 - 01/2005)|
|8.||Szweda, Luke I: 2 articles (04/2009 - 01/2007)|
|9.||Matsuzaki, Satoshi: 2 articles (04/2009 - 01/2007)|
|10.||Yagiz, Kader: 2 articles (12/2008 - 05/2007)|
|1.||Coronary Artery Disease (Coronary Atherosclerosis)
06/01/2002 - "Blood pressure is partly controlled by O(-)(2) production by NADPH/NADH oxidase and recently it was shown that a C242T substitution in the p22phox gene was associated with coronary artery disease, in which elevated blood pressure and oxidative stress are also important pathophysiologic features. "
09/01/2011 - "Important protective effects on circulating lipoproteins and in the prevention of coronary artery disease ensue not only from the antioxidant role of CoQ(10) but also from its ability to directly block protein oxidation and superoxide generation of the TM-9 family of membrane proteins known as age-related NADH oxidase or arNOX (ENOX3) and their shed forms that appear after age 30 and some of which associate specifically with low-density lipoprotein particles to catalyze protein oxidation and crosslinking."
02/01/2014 - "A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors."
02/01/2014 - "ME-143, a second-generation tumor-specific NADH oxidase inhibitor, is broadly active against human cancers in vitro and in vivo. "
04/01/2009 - "Early developmental expression of a normally tumor-associated and drug-inhibited cell surface-located NADH oxidase (ENOX2) in non-cancer cells."
05/15/2007 - "Mouse embryonic fibroblast (MEF) cells prepared from transgenic mice overexpressing a cancer-specific and growth-related cell surface NADH oxidase with protein disulfide-thiol interchange activity grew at rates approximately twice those of wild-type embryonic fibroblast cells. "
06/26/2001 - "Cancer isoform of a tumor-associated cell surface NADH oxidase (tNOX) has properties of a prion."
01/01/2007 - "After 4 weeks of hyperglycemia one marker of mitochondrial function, NADH oxidase activity, was decreased to 50% of control animals. "
04/01/2003 - "In the aorta from old OLETF rat with hyperglycemia, the enhanced NADH oxidase activity in association with upregulated expression of p22phox and gp91phox was observed, but not in both LETO and young (10 weeks) OLETF rats without hyperglycemia. "
04/01/2003 - "Based on these results, it was suggested that the enhanced NADH oxidase activity in the aorta from OLETF rat occurred after the onset of hyperglycemia, thereby resulting in the increased vascular production of superoxide."
01/01/2000 - "These results support that hyperglycemia is one factor that induces retinal endothelial cells in vivo to increase H2O2 via NADH oxidase and stimulates increases in VEGF resulting in disruption of the BRB."
05/01/2002 - "Colloidal gold-labeled immunocytochemical studies of iNOS and nitrotyrosine, a marker for OONO(-), were done on sections of retinas from male BBZ/Wor rats in which NADH oxidase was localized by cerium derived cytochemistry at three time points: pre-diabetes (prior to the onset of hyperglycemia); new onset diabetes (2-6 days after onset of hyperglycemia); and chronic diabetes (4-18 months after onset of hyperglycemia). "
01/01/2010 - "Based on previous computer-aided drug design (CADD) studies and considering reported data on structure-activity relationships (SAR), an assumption regarding the mechanism of action of natural products against parasitic infections involves the NADH-oxidase inhibition. "
11/01/2006 - "As the nox2 defect seems only to affect aerobic growth of GBS, its reduced virulence supports the suggestion that aerobic conditions and NADH oxidase activities are relevant to the GBS infection process."
02/01/2001 - "Characterization of the Streptococcus pneumoniae NADH oxidase that is required for infection."
02/01/2001 - "NADH oxidase, a factor necessary for infection, was previously identified as part of a signature-tagged mutagenesis screen of a S. "
02/01/2001 - "A complete refined nox deletion mutant was generated by allelic-replacement mutagenesis and found to be attenuated for virulence 10(5)-fold in the murine respiratory tract infection model and at least 10(4)-fold in a Mongolian gerbil otitis media infection model, confirming the importance of the NADH oxidase for both types of S. "
|2.||Membrane Proteins (Integral Membrane Proteins)
|4.||coenzyme Q10 (CoQ10)
|8.||Peroxynitrous Acid (Peroxynitrite)
|9.||Electron Transport Complex IV (Cytochrome c Oxidase)
|1.||Drug Therapy (Chemotherapy)